AWA
SRPT icon

Arkadios Wealth Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Arkadios Wealth Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-75
Closed -$6K – 1623
2021
Q3 		$6K Hold
75
– – ﹤0.01% 1565
2021
Q2 		$5K Hold
75
– – ﹤0.01% 1740
2021
Q1 		$5K Sell
75
-650
-90% -$60K ﹤0.01% 1381
2020
Q4 		$123K Buy
725
+650
+867% +$96.3K 0.03% 405
2020
Q3 		$10.7K Hold
75
– – 0.01% 735
2020
Q2 		$12.5K Hold
75
– – 0.01% 637
2020
Q1 		$7.34K Hold
75
– – ﹤0.01% 701
2019
Q4 		$9.38K Buy
+75
New +$7.57K 0.01% 604

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Arkadios Wealth Advisors's SRPT Position: Q4 2021 in Review

Arkadios Wealth Advisors sold out of Sarepta Therapeutics (SRPT) in Q4 2021, closing a stake of 75 shares — an estimated $6K sold.

Arkadios Wealth Advisors first reported a position in SRPT in Q4 2019 and held it in 8 quarters. The position peaked at $123K in Q4 2020. 343 funds tracked by Wall St. Rank hold SRPT as of Q4 2021.

  • Arkadios Wealth Advisors reported no remaining Sarepta Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Arkadios Wealth Advisors sold 75 Sarepta Therapeutics shares in Q4 2021, an estimated $6K.
  • Arkadios Wealth Advisors first reported a position in Sarepta Therapeutics in Q4 2019 and held it in 8 quarters.
  • Arkadios Wealth Advisors's Sarepta Therapeutics position peaked at $123K in Q4 2020.
  • 343 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2021.

Based on Arkadios Wealth Advisors's 13F filing for Q4 2021, filed 3 Feb 2022.